Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
25 févr. 2022 02h00 HE
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma If approved by the European Medicines Agency,...
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
26 janv. 2022 07h00 HE
|
Immunocore Holdings Limited
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanomaKIMMTRAK is the first and only FDA approved therapy for the treatment of...
Immunocore to present at the 40th Annual J.P. Morgan Healthcare Conference
06 janv. 2022 07h00 HE
|
Immunocore Holdings Limited
Immunocore to present at the 40th Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 6 January 2022) Immunocore Holdings Plc (Nasdaq:...
Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4
06 déc. 2021 07h00 HE
|
Immunocore Holdings Limited
Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4 Clinical activity with confirmed durable responses in ovarian cancer and a confirmed durable...
Immunocore Reports First Quarter 2021 Financial Results
12 mai 2021 07h00 HE
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Reports First Quarter 2021 Financial Results Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) is expected to be completed in...
Immunocore announces key appointments to management and Board
16 févr. 2021 07h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore announces key appointments to management and Board Ralph Torbay appointed Head of Commercial to spearhead the launch of tebentafusp Dr. Roy S. Herbst appointed as a...
Immunocore announces closing of $75.0 Million Series C round
11 janv. 2021 07h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore announces closing of $75.0 Million Series C round Funding follows positive Phase 3 trial interim analysis data for tebentafusp in patients with metastatic uveal melanoma ...